PURPOSE: The ability of two semi-mechanistic simulation approaches to predict the systemic pharmacokinetics (PK) of inhaled corticosteroids (ICSs) delivered via dry powder inhalers (DPIs) was assessed for mometasone furoate, budesonide and fluticasone propionate. METHODS: Both approaches derived the total lung doses and the central to peripheral lung deposition ratios from clinically relevant cascade impactor studies, but differed in the way the pulmonary absorption rate was derived. In approach 1, the rate of in vivo drug dissolution/absorption was predicted for the included ICSs from in vitro aerodynamic particle size distribution and in vitro drug solubility estimates measured in an in vivo predictive dissolution medium. Approach 2 derived a first order absorption rate from the mean dissolution time (MDT), determined for the test formulations in an in vitro Transwell® based dissolution system. RESULTS: Approach 1 suggested PK profiles which agreed well with the published pharmacokinetic profiles. Similarly, within approach 2, input parameters for the pulmonary absorption rate constant derived from dissolution rate experiments were able to reasonably predict the pharmacokinetic profiles published in literature. CONCLUSION: Approach 1 utilizes more complex strategies for predicting the dissolution/absorption process without providing a significant advantage over approach 2 with regard to accuracy of in vivo predictions.
PURPOSE: The ability of two semi-mechanistic simulation approaches to predict the systemic pharmacokinetics (PK) of inhaled corticosteroids (ICSs) delivered via dry powder inhalers (DPIs) was assessed for mometasone furoate, budesonide and fluticasone propionate. METHODS: Both approaches derived the total lung doses and the central to peripheral lung deposition ratios from clinically relevant cascade impactor studies, but differed in the way the pulmonary absorption rate was derived. In approach 1, the rate of in vivo drug dissolution/absorption was predicted for the included ICSs from in vitro aerodynamic particle size distribution and in vitro drug solubility estimates measured in an in vivo predictive dissolution medium. Approach 2 derived a first order absorption rate from the mean dissolution time (MDT), determined for the test formulations in an in vitro Transwell® based dissolution system. RESULTS: Approach 1 suggested PK profiles which agreed well with the published pharmacokinetic profiles. Similarly, within approach 2, input parameters for the pulmonary absorption rate constant derived from dissolution rate experiments were able to reasonably predict the pharmacokinetic profiles published in literature. CONCLUSION: Approach 1 utilizes more complex strategies for predicting the dissolution/absorption process without providing a significant advantage over approach 2 with regard to accuracy of in vivo predictions.
Entities:
Keywords:
dissolution; in vitro/in vivo; inhalation; inhaled corticosteroids; solubility
Authors: H Möllmann; M Wagner; S Krishnaswami; H Dimova; Y Tang; C Falcoz; P T Daley-Yates; M Krieg; R Stöckmann; J Barth; C Lawlor; A C Möllmann; H Derendorf; G Hochhaus Journal: J Clin Pharmacol Date: 2001-12 Impact factor: 3.126
Authors: Jayne E Hastedt; Per Bäckman; Antonio Cabal; Andy Clark; Carsten Ehrhardt; Ben Forbes; Anthony J Hickey; Guenther Hochhaus; Wenlei Jiang; Stavros Kassinos; Philip J Kuehl; David Prime; Yoen-Ju Son; Simon Teague; Ulrika Tehler; Jennifer Wylie Journal: Mol Pharm Date: 2022-05-16 Impact factor: 5.364
Authors: Mireille Hassoun; Paul G Royall; Mark Parry; Richard D Harvey; Ben Forbes Journal: J Drug Deliv Sci Technol Date: 2018-10 Impact factor: 3.981
Authors: Khaled Almansour; Iman M Alfagih; Alhassan H Aodah; Fawaz Alheibshy; Raisuddin Ali; Turki Al Hagbani; Mustafa M A Elsayed Journal: Pharmaceutics Date: 2021-12-30 Impact factor: 6.321